While this study was the first to suggest that testosterone treatment was associated with a decreased risk for aggressive prostate cancer interpretation is challenging given the lack of data on testosterone levels and frequency of PSA assessment in both cases and controls. Here, KLK3 is linked to prostate carcinoma.